Comparison
CJC-1295 vs. Octreotide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Research other
CAS no.
no data
83150-76-9
Molecular weight
3647.3 g/mol
1019.24 g/mol
Half-life
144 h
1.7 h
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSR-DACD-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)Mechanism of action
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
Octreotide
Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).
Evidence base
Highest evidence
Human trial
Human RCT
Studies
3
5
of which in humans
2
4
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
3
2